Phase II Study of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal Cancer

Bristol-Myers Squibb (BMS)

Status and phase: Completed; Phase 2

Conditions: Esophageal Cancer

Treatments: Drug: Paclitaxel

Study type: Interventional

Funder types: Industry

Identifiers

NCT00344552

CA139-540

Details and patient eligibility

About

The purpose of this clinical research study is to learn if BMS-181339 can shrink or slow the growth of the cancer in patients with advanced or recurrent esophageal cancer. The safety of this treatment will also be studied.

Enrollment: 53 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients must have measurable disease
• Patients must have experienced on pervious chemotherapy regime
• Men and Women, with the age 20 years or older
• ECOG PS: 0-1

Exclusion criteria

• Patients with previous therapy with Taxanes

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

53 participants in 1 patient group

1

Experimental group

Treatment:

Drug: Paclitaxel